Licence extension for Decapeptyl SR

Licence changes apply to Decapeptyl SR 3mg and 11.25mg presentations
Licence changes apply to Decapeptyl SR 3mg and 11.25mg presentations

In addition to use in metastatic prostate cancer and as an alternative to castration in locally advanced prostate cancer, Decapeptyl SR (triptorelin) is now licensed for use as an adjunct to radiotherapy in high-risk localised or locally advanced prostate cancer.

The approved dose of the prolonged-release GnRH analogue is 3mg every 28 days or 11.25mg every 3 months, by intramuscular injection. The six-monthly 22.5mg presentation is not currently licensed for the new indication.

View Decapeptyl SR drug record

Further Information: Ipsen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases